Combined Erlotinib and PF-03084014 treatment contributes to synthetic lethality in head and neck squamous cell carcinoma.
about
Combined Erlotinib and PF-03084014 treatment contributes to synthetic lethality in head and neck squamous cell carcinoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Combined Erlotinib and PF-0308 ...... neck squamous cell carcinoma.
@en
Combined Erlotinib and PF-0308 ...... neck squamous cell carcinoma.
@nl
type
label
Combined Erlotinib and PF-0308 ...... neck squamous cell carcinoma.
@en
Combined Erlotinib and PF-0308 ...... neck squamous cell carcinoma.
@nl
prefLabel
Combined Erlotinib and PF-0308 ...... neck squamous cell carcinoma.
@en
Combined Erlotinib and PF-0308 ...... neck squamous cell carcinoma.
@nl
P2093
P2860
P356
P1433
P1476
Combined Erlotinib and PF-0308 ...... d neck squamous cell carcinoma
@en
P2093
Yang Zheng
P2860
P304
P356
10.1111/CPR.12424
P577
2017-12-12T00:00:00Z